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Abstract 
Hashimoto's encephalopathy (HE) is a rare condition characterized by atypical psychiatric and heterogeneous neu-
rological manifestations such as acute cerebral ischemia, seizure, tremors, myoclonus, psychosis, depression, cogni-
tive disorders, and fluctuating loss of consciousness. Here, a case of 28 year-old man was reported who referred to 
the emergency department (ED) with different acute neurologic disorders and final diagnose of HE. 
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Introduction: 1 
ashimoto's encephalopathy (HE) is a rare condi-
tion characterized by atypical psychiatric and 
heterogeneous neurological manifestations such 
as acute cerebral ischemia, seizure, tremors, myoclonus, 
psychosis, depression, cognitive disorders, and fluctuat-
ing loss of consciousness (1-3). Despite a wealth of 
studies identifying the etiology of HE, its exact patho-
genesis is not still completely understood (4, 5). Due to 
non-specific findings it is often considered to be a diag-
nosis of exclusion. Currently, HE is considered to be a 
treatable dementia but there is no consensus on the 
duration or drug of choice for treatment. Here, a case of 
28 year-old man was reported who referred to the 
emergency department (ED) with different acute neuro-
logic disorders and final diagnose of HE. 
Case report: 
A previously healthy 28 year-old man was referred to the 
ED with a history of ophthalmoplegia and ataxia followed 
by progressive cognitive impairment. Two months prior 
to this episode, mild neck pain and sore throat were the 
only findings in his past medical history. He had no histo-
ry of alcohol consumption, substance abuse, medication 
use, congenital disease, syncope, ischemic or hemorrhag-
ic cerebrovascular attract, seizure, trauma, or any other 
known medical problems. The patients’ on-arrival vital 
signs were as follow: systolic blood pressure (SBP): 120 
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mmHg, pulse rate (PR): 90/minute, respiratory rate 
(RR): 14/minute, oral temperature: 37.5◦C, oxygen satu-
ration 96% with nasal cannula and 100% oxygen, and 
Glasgow coma scale (GCS) 15/15. Physical examination 
revealed jerky movements in limbs, normal size and re-
active pupils, fluctuating disorientation, severe cerebral 
ataxia, bilateral sixth nerve and upward gaze palsy, and 
increased deep tendon reflexes. A mini mental state ex-
amination resulted in 10 of 30 points. The patients’ head 
and neck examination, lung and heart sounds, four limbs 
pulses, and capillary refile were normal. After assess-
ment of airway, breathing, and circulation (ABC) patients 
were checked in terms of coma cocktail. Blood sugar was 
measured 100 mg/dl with glucometer. Electrocardiog-
raphy (ECG) revealed normal sinus rhythm with normal 
axis. Brain computed tomography had not any abnormal 
findings, but bilateral hyper-signal white matter lesions 
were detected on fluid attenuation inversion recovery 
(FLAIR) and T2 weighted magnetic resonance imaging 
(MRI) (Figure 1). Cerebrospinal fluid (CSF) analysis re-
sults were as follows: protein: 170 mg/dl, glucose: 67 
mg/dl, cell count: 80/mm3 with lymphocyte dominancy. 
All of laboratory parameters as cell blood count, coagula-
tion profile, kidney and liver function tests, venous blood 
gas parameters, and electrolyte were in normal range. 
Neurology consult was taken and patient admitted in 
neurology ward for further evaluations. Electroenceph-
alography showed abnormal nonspecific sharp and spike 
waves in a slow background. Neural antibodies such as 
anti–N-methyl-D-aspartate receptor (NMDAR) were neg-
ative. Thyroid statues demonstrated subclinical hypothy-
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ies were 220 IU/ml and 740 IU/ml, respectively, which 
were significantly higher than normal ranges. All other 
assessments were normal. Taking the above data into 
consideration and excluding other differential diagnosis, 
HE was presumed. The patient underwent ten days of 
Methyl Prednisolone pulse regime (one gram per day) 
with tapering Prednisolone (120 mg orally per day) for 
two weeks. All signs and symptoms especially cognition 
and ophthalmoplegia dramatically improved and white 
matter lesions disappeared after two weeks of treatment 
(Figure 2).  
Discussion: 
Heterogeneous clinical manifestations and absence of 
non-specific tests have made the HE diagnosis as a chal-
lenging problem for physicians. Susan lee et al. in a re-
view concluded that psychiatrists should be aware of 
this often unrecognized entity to ensure accurate diag-
nosis and timely treatment (6). HE has different MRI 
manifestations from normal appearance to demye-
lination, ischemic lesions, edema, and atrophy (7). Usu-
ally, HE is diagnosed by high levels of anti-TPO antibod-
ies, normal T4, and thyroid stimulating hormone (TSH) 
titers in the presence of above mentioned heterogene-
ous clinical manifestations (8). Recent studies have 
suggested cerebrospinal fluid titer of anti-thyroid anti-
bodies as a pathognomonic test for HE (1, 9). According 
to the published case series, steroid is the only accepted 
treatment for this disease and among 81 adults and 
children, about 50% of patients recovered completely 
and the other cases relapsed or improved with residual 
deficits (10, 11). Previous studies have recommended 
three to five days corticosteroids (12). The present 
study is the first one that give the patient 10 days of 
Methyl Prednisolone. The patient responded completely 
to the corticosteroid. It seems that a favorable progno-
sis may depend upon rapid recognition of HE and ag-
gressive steroid treatment. However, further studies 
are needed to evaluate the advantage of this type of 
treatment for disease. 
Conclusion: 
In the case of unknown psychiatric and neurologic man-
ifestations, measuring serum level of thyroid hormones 
and CSF titer of anti-thyroid antibodies could be helpful 
in limitation of differential diagnosis and timely initia-
tion of proper treatment. 
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Figure 1: Fluid attenuation inversion recovery shows sym-
metric white matter lesion before treatment  
 
Figure 2: Fluid attenuation inversion recovery shows im-
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